Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREDICT: Eplerenone in Diastolic Heart Failure
NCT00293150Phase 4Terminated
- Sponsor
- Cleveland Clinic
- Start
- Sep 2003
- Primary completion
- Sep 2007
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) comparing Eplerenone with Placebo (2 arms). Primary endpoint: Efficacy of eplerenone at 9 months. Started Sep 2003; status: terminated.
02
Drugs
eplerenone
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT00293150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00293150.